Changes in Beneficial Ownership · 4
Veradermics, Incorporated
MANENYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1786744911.xml
Filing details
- Report period
- 2026-08-12
- Issuer
- Veradermics, Inc
- Issuer CIK
- 0001827635
- Trading symbol
- MANE
Reporting owner 1
- Name
- CHILDS JOHN W
- Reporting owner CIK
- 0001027035
- Relationship
- Director
- Address
- C/O VERADERMICS, INCORPORATED, 470 JAMES ST., NEW HAVEN, CT, 06513
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-12 | S · Form 4 | 15,000 | D | 106.14[F1] | 279,117 | I | See Footnote[F2] |
| Common Stock | 2026-08-12 | S · Form 4 | 80,000 | D | 107.23[F3] | 199,117 | I | See Footnote[F2] |
| Common Stock | 2026-08-12 | S · Form 4 | 5,000 | D | 108.24 | 194,117 | I | See Footnote[F2] |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Disposed
- I
- Indirect
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 1,907,889 | I | See Footnote[F4] |
Table key
- I
- Indirect
Footnotes
- F1
- The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.77 to $106.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F2
- Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.↩ 1↩ 2↩ 3
- F3
- The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.04 to $107.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F4
- Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.↩ 1
Signature 1
- Signed
- /s/ Michael Greco, Attorney-in-Fact
- Date
- 2026-08-14
Company context
We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation. Patients and healthcare providers routinely identify the following shortcomings with currently available treatment options: